Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Statins and coronary heart disease.

Fey R, Pearson N.

Lancet. 1996 May 18;347(9012):1389-90. No abstract available.

PMID:
8637349
2.

Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.

Elam MB, Cushman W, Applegate WB, Heimberg M.

Tenn Med. 1997 May;90(5):189-92. No abstract available.

PMID:
9130876
3.

Cholesterol and coronary heart disease: new data from the WOSCOP Study.

Poli A.

Pharmacol Res. 1997 Mar;35(3):171-2. No abstract available.

PMID:
9229403
4.

Statins prevent coronary heart disease.

Oliver MF.

Lancet. 1995 Nov 25;346(8987):1378-9. No abstract available. Erratum in: Lancet 1996 Jan 6;347(8993):68.

PMID:
7475814
5.

[Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].

Poli A, Menotti A.

G Ital Cardiol. 1999 Oct;29(10):1123-30. Review. Italian. No abstract available.

PMID:
10546121
6.
7.

Statins for stroke: the second story?

Plutzky J, Ridker PM.

Circulation. 2001 Jan 23;103(3):348-50. No abstract available.

8.

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Lennernäs H, Fager G.

Clin Pharmacokinet. 1997 May;32(5):403-25. Review.

PMID:
9160173
9.

Preventing the next event in the elderly: the PROSPER perspective.

Shepherd J.

Atheroscler Suppl. 2003 Dec;4(5):17-22.

PMID:
14980231
10.
11.

[Statin treatment in type 2 diabetes. Is it a must today?].

Faust M.

MMW Fortschr Med. 2003 Feb 27;145(9):35-6. German. No abstract available.

PMID:
12666527
12.

Summaries for patients. Benefits of lowering cholesterol levels in older patients.

[No authors listed]

Ann Intern Med. 2001 May 15;134(10):S-4. No abstract available.

PMID:
11357858
13.

More on PROSPER.

Wierzbicki AS, Mikhailidis DP, Reynolds TM.

Lancet. 2003 Mar 29;361(9363):1135-6; author reply 1136. No abstract available.

PMID:
12672344
14.

Pravastatin and coronary heart disease.

Bloom JM.

N Engl J Med. 1999 Apr 8;340(14):1116-7. No abstract available.

PMID:
10206831
16.

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.

Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD.

Circulation. 2000 Oct 17;102(16):1893-900.

17.

More on PROSPER.

Baztán JJ, Hornillos M, Rodríguez-Mañas L.

Lancet. 2003 Mar 29;361(9363):1135; author reply 1136. No abstract available.

PMID:
12672345
18.

[Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].

Sato S, Matsushita Y, Kobayashi T, Awata N.

Nihon Eiseigaku Zasshi. 2004 Jul;59(3):335-41. Japanese.

PMID:
15359898
19.
20.

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators.

Circulation. 2002 Mar 12;105(10):1162-9.

Supplemental Content

Support Center